Advances in population-based studies

Stroke

Volumn 41, Issue 2, 2010, Pages

  Truelsen, Thomas ^a  

^a Department of Neurology ^*  (Denmark)

Author keywords

Advances; Population based studies; Risk factors

Indexed keywords

C REACTIVE PROTEIN; GLUCOCORTICOID; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG MEGADOSE; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MORTALITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK FACTOR; SHORT SURVEY; SMOKING CESSATION; SOUTH AFRICA; STROKE; UNITED STATES; AMERICAN INDIAN; COHORT ANALYSIS; GENETICS; GEOGRAPHY; METABOLISM; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REVIEW; SMOKING; STATISTICS;

ATRIAL FIBRILLATION; C-REACTIVE PROTEIN; COHORT STUDIES; EUROPE; GEOGRAPHY; GLUCOCORTICOIDS; HUMANS; INDIANS, NORTH AMERICAN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SMOKING; STROKE;

EID: 77449159404     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.572511     Document Type: Short Survey

References (15)

1. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-495.
2. Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik SL, Paik MC, Sacco RL. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology. 2009;20:73: 1300-1307.
3. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
4. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sorensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009; 169:1677-1683.
5. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078-3084.
6. Truelsen T, Bonita R, Jamrozik K. Surveillance of stroke: a global perspective. Int J Epidemiol. 2001;30(suppl 1):S11-S16.
7. Horner RD, Day GM, Lanier AP, Provost EM, Hamel RD, Trimble BA. Stroke mortality among Alaska Native people. Am J Public Health. 2009;99:1996-2000.
8. Liao Y, Greenlund KJ, Croft JB, Keenan NL, Giles WH. Factors explaining excess stroke prevalence in the US Stroke Belt. Stroke. 2009; 40:3336-3341.
9. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288:1388-1395.
10. Gall SL, Dewey HM, Thrift AG. Smoking cessation at 5 years after stroke in the North East Melbourne stroke incidence study. Neuroepidemiology. 2009;32:196-200.
11. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ. 2009; 339:b3060.
12. Connor MD, Modi G, Warlow CP. Differences in the nature of stroke in a multiethnic urban South African population: the Johannesburg Hospital Stroke Register. Stroke. 2009;40:355-362.
13. Truelsen T, Piechowski-Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006;13:581-598.
14. Incidence of stroke in Europe at the beginning of the 21st century. Stroke. 2009;40:1557-1563.
15. Kleindorfer D, Khoury J, Broderick JP, Rademacher E, Woo D, Flaherty ML, Alwell K, Moomaw CJ, Schneider A, Pancioli A, Miller R, Kissela BM. Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment. Stroke. 2009;40:2502-2506.